SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study was to compare the efficacy and safety of camrelizumab + apatinib
mesylate neoadjuvant therapy combined with camrelizumab adjuvant therapy and camrelizumab
adjuvant therapy alone in patients with technically resectable hepatocellular carcinoma.